Lovelace Biomedical Research Institute
Lovelace Biomedical Research Institute received $2.1M in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 89.1% from $18.9M the year before, and $41.4M since FY2022. Its largest customer is the Department of Health and Human Services.
See 6 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- MBT9RXJJ7428
- CAGE code
- 3MMH4
- Doing business as
- Inhalation Toxicology RES Inst
- Headquarters
- Albuquerque, NM
- Business size
- Other Than Small Business
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Markets where it ranks top 10
Agency and NAICS markets where this UEI is one of the ten largest primes in the latest 12 months.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Health and Human Services | $2.0M | $40.6M |
| Department of Defense | $44K | $767K |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | $4.2M | $10.8M |
| 541690 | Other Scientific and Technical Consulting Services | $3.0M | $10.3M |
| 541380 | Testing Laboratories and Services | −$7.2M | $9.8M |
| 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | $795K | $8.3M |
| 541712 | Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) | $1.3M | $2.8M |
| 511210 | Software Publishers | $44K | $742K |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| B529 | Special Studies/Analysis- Scientific Data | $17.7M |
| AN11 | Health R&D services; Health Care services; Basic Research | $10.5M |
| AN13 | Health R&D services; Health Care services; Experimental Development | $8.4M |
| R499 | Support- professional: Other | $2.1M |
| AN42 | Health R&D services; Health Care - other; Applied Research | $1.1M |
| AN22 | Health R&D services; Health Research and training; Applied Research | $766K |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 75F40122F19001 | Department of Health and Human Services CTP-2022-111127 - SALTS | $2.1M | Feb 22, 2027 |
| 75A50123F61001 | Department of Health and Human Services RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE… | $5.9M | Apr 17, 2027 |
| 75N95020F00001 | Department of Health and Human Services NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA,… | $3.0M | May 31, 2027 |
| 75N95021F00001 | Department of Health and Human Services CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $1.0M | Jun 30, 2027 |
| 75F40125P00216 | Department of Health and Human Services SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | $7.1M | Sep 29, 2027 |
| 75F40123F19002 | Department of Health and Human Services TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR | $1.3M | Sep 29, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 75N98026F00001 | Department of Health and Human Services GLP REPEAT DOSE TOXICOLOGY STUDY FOR A LIVE-ATTENUATED RESPIRATORY VIRUS VACCINE. | $340K | Sep 25, 2026 |
| 75F40126F19003 | Department of Health and Human Services NICOTINE FLUX: INVESTIGATING THE IMPACT OF ENDS OUTPUT POWER AND HEATING ELEMENT ON ABUSE LIABILITY | $3.0M | Sep 14, 2026 |
| 75A50126F61002 | Department of Health and Human Services RTOR BIO-AMT-2312: ASSESSMENT OF THE THERAPEUTIC POTENTIAL OF CHLOROQUINE AND OSELTAMIVIR IN TWO (2) LETHAL MODELS OF INFLUENZA A H5N1 | $3.7M | Aug 21, 2026 |
| 75F40125P00216 | Department of Health and Human Services SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | $7.1M | Sep 19, 2025 |
| 75N92024P00303 | Department of Health and Human Services 24-015894 NHLBI POPULATION SCIENCES BRANCH REQUIRES PULMONARY FUNCTION TESTING TO DETERMINE IF THE FLEXIVENT METHOD OF PULMONARY FUNCTION TESTING IS SUITABLE TO BE USED IN A… | $17K | Aug 27, 2024 |
| 75N95024F00001 | Department of Health and Human Services KICK-OFF MEETING FOR THE PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT IDIQ CONTRACT. | $1K | Aug 6, 2024 |
| 75N95024F00002 | Department of Health and Human Services RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH… | $211K | Mar 20, 2024 |
| 75N95024F00001 | Department of Health and Human Services EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025. | $141K | Mar 20, 2024 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.